Abstract
The article discusses modern approaches in the treatment of HER2-positive breast cancer (BC) with brain metastases (BM).The patients are subject to multidisciplinary, comprehensive and biologically – oriented treatment, with the involvement of a neurosurgeon and a radiation therapist to make a decision considering local treatment of BM, as well as a clinical oncologist to choose systemic drug therapy. Local treatment of HER2+ BC with BM patients includes surgical treatment and/or radiotherapy. Use of targeted anti-HER2 therapy changes “biology” of the disease from aggressive to indolent.In the prospective KAMILLA trial, clinically significant antitumor activity of trastuzumab emtansine was found for the first time both in patients with HER2+ BC with BM, who were previously treated with radiotherapy, and without radiotherapy in the anamnesis, which suggests the validity of further use of trastuzumab emtansine in this category of patients.The antitumor activity of trastuzumab emtansine in patients with HER2+ BC with BM was also confirmed in preclinical models. Despite the similar drug distribution in the tissues, trastuzumab emtansine, in contrast to trastuzumab, significantly slowed the growth of metastases, causing the induction of apoptosis in HER2+ BC models with BM in mice.
Highlights
В статье рассматриваются современные подходы к лечению больных HER2‐положительным раком молочной железы (HER2+ Рак молочной железы (РМЖ)) с метастазами в головном мозге (МГМ)
In the prospective KAMILLA trial, clinically significant antitumor activity of trastuzumab emtansine was found for the first time both in patients with HER2+ breast cancer (BC) with brain metastases (BM), who were previously treated with radiotherapy, and without radiotherapy in the anamnesis, which suggests the validity of further use of trastuzumab emtansine in this category of patients
The antitumor activity of trastuzumab emtansine in patients with HER2+ BC with BM was confirmed in preclinical models
Summary
В статье рассматриваются современные подходы к лечению больных HER2‐положительным раком молочной железы (HER2+ РМЖ) с метастазами в головном мозге (МГМ). Локальное лечение больных HER2+ РМЖ с МГМ включает хирургическое лечение и / или лучевую терапию. В проспективном исследовании KAMILLA была впервые продемонстрирована клинически значимая противоопухолевая активность трастузумаба эмтанзина как у больных HER2+ РМЖ с МГМ, ранее получавших лучевую терапию, так и у пациентов без лучевой терапии в анамнезе, что позволяет предполагать обоснованность дальнейшего применения трастузумаба эмтанзина у данной категории больных. Противоопухолевая активность трастузумаба эмтанзина у больных HER2+ РМЖ c МГМ была подтверждена и на доклинических моделях. Ключевые слова: HER2+ рак молочной железы, метастазы в головном мозге, T-DM1, трастузумаб эмтанзин, анти-HER2 терапия. Для цитирования: Семиглазова Т.Ю., Шарашенидзе С.М., Керимова С.Н. Современные подходы к лечению больных HER2‐положительным раком молочной железы с метастазами в головном мозге. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia; 6–8 Lva Tolstogo St., Saint Petersburg 197022, Russia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
